Accessibility Menu
Medexus Pharmaceuticals logo

Medexus Pharmaceuticals(TSX) MDP

Market CapCA$159.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-33%
5 Year+16%
1 Year+63%
1 Month+6%
CA$5.06
-1.37%
-0.07Today
Medexus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeCAD 5.062026-08-28
Medexus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.56%CAD 5.142026-08-21
1 month+5.86%CAD 4.782026-07-29
3 month+30.41%CAD 3.882026-05-29
Year to date+73.88%CAD 2.912025-12-31
1 year+62.7%CAD 3.112025-08-28
3 year+72.11%CAD 2.942023-08-29
5 year+16.32%CAD 4.352021-08-27
Since inception-32.53%CAD 7.502013-12-27

Medexus Pharmaceuticals Financials at a Glance

Market Cap

CA$159.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$102.56M

Net Income (TTM)

-$2.38M

EPS (TTM)

-CA$0.10

P/E Ratio

-50.15

Dividend

CA$0.00

Beta (Volatility)

0.90 (Low)

Price

CA$5.06

Volume

34,404

Open

CA$5.14

Previous Close

CA$5.06

Daily Range

CA$5.02 - CA$5.14

52-Week Range

CA$2.51 - CA$5.50

Estimated Earnings Date

Nov 11, 2026

MDP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States, focusing on various therapeutic areas including allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. The company offers a diverse portfolio of products aimed at addressing significant medical needs.

Products and Services
  • IXINITY, a therapeutic for hemophilia B
  • Rasuvo and Metoject, treatments for rheumatoid arthritis
  • Gleolan, an optical imaging agent for glioma surgery
Growth Outlook
  • Recent quarterly revenue increased to $27.8 million, reflecting strong demand
  • Gross profit margin improved to 55.4%, indicating operational efficiency
  • Expansion into new therapeutic areas is expected to drive future growth
Financial Highlights
  • Trailing twelve months revenue of $99.5 million, showcasing consistent performance
  • Net income of $530,000 in the latest quarter, a positive shift from previous losses
  • Current ratio of 1.30, indicating solid short-term financial health
Medexus Pharmaceuticals Inc. has established itself as a key player in the pharmaceutical industry, with a focus on innovative treatments across multiple therapeutic areas. The company's recent financial performance demonstrates a positive trajectory, with increasing revenues and improving profit margins. The strategic expansion into new markets and therapeutic areas positions Medexus for continued growth, making it an intriguing option for potential investors. The company's commitment to addressing unmet medical needs through its diverse product offerings further enhances its appeal in the competitive pharmaceutical landscape.
AI Generated • Aug 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

90

CEO

Kenneth d’Entremont

Website

www.medexus.com

Headquarters

Toronto, ON M5C 1C3, CA

MDP Financials

Key Financial Metrics (TTM)

Gross Margin

54.66%

Operating Margin

6.62%

Net Income Margin

-2.32%

Return on Equity

-4.72%

Return on Capital

8.19%

Return on Assets

-1.68%

Earnings Yield

-1.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$159.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.43M

Volume

34.40K

Avg. Volume

48.40K

Financials (TTM)

Gross Profit

$56.06M

Operating Income

$6.79M

EBITDA

$12.56M

Operating Cash Flow

$13.84M

Capital Expenditure

-$15.05M

Free Cash Flow

-$1.21M

Cash & ST Invst.

$5.34M

Total Debt

$26.21M

Medexus Pharmaceuticals Performance Analysis

Medexus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 142,998,44548.7%
20242024-03-31USD 152,490,6276.6%
20252025-03-31USD 150,683,099-1.2%
20262026-03-31USD 137,286,374-8.9%
Medexus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-300.5%
Q32025-12-312.4%
Q42026-03-31-2.7%
Q12026-06-3013.0%
Medexus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD 0.08N/A
20242024-03-31USD -0.01N/A
20252025-03-31USD 0.12N/A
20262026-03-31USD -0.10N/A
Medexus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-162.5%
Q32025-12-31125.0%
Q42026-03-31-3540.0%
Q12026-06-30119.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

$27.85M

+13.1%

Gross Profit

$15.42M

+12.0%

Gross Margin

55.39%

N/A

Market Cap

CA$159.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$1.77M

N/A

Employees

90

N/A

Net Income

$529.96K

+2.7%

EBITDA

$4.41M

-0.8%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

$5.34M

-42.8%

Total Debt

$26.21M

+19.7%

Accounts Receivable

$13.07M

+5.7%

Inventory

$29.82M

-15.8%

Long Term Debt

$23.82M

+14882.5%

Short Term Debt

$2.39M

-89.0%

Return on Assets

-1.68%

N/A

Return on Invested Capital

7.02%

N/A

Free Cash Flow

-$1.14M

-130.0%

Operating Cash Flow

-$1.12M

-128.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DB.VDecibel Cannabis Company Inc.
CA$0.12+0.00%
CRDL.TOCardiol Therapeutics Inc.
CA$2.70-5.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$49.82+0.10%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.34-0.10%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.54+0.02%
INTCIntel
$89.47-0.03%

Questions About MDP

What is the current price of Medexus Pharmaceuticals?

Medexus Pharmaceuticals is trading at CA$5.06 per share.

What is the 52-week range for Medexus Pharmaceuticals?

Over the past 52 weeks, Medexus Pharmaceuticals has traded between CA$2.51 and CA$5.50.

How much debt does Medexus Pharmaceuticals have?

As of the most recent reporting period, Medexus Pharmaceuticals reported total debt of $37.25M.

How much cash does Medexus Pharmaceuticals have on hand?

Medexus Pharmaceuticals reported $7.58M in cash and cash equivalents in its most recent financial results.

What is Medexus Pharmaceuticals’s dividend yield?

Medexus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services